Warhound, a US-based defence technology startup, has raised $200 million in seed funding to develop genetically engineered and cloned working dogs for military, law enforcement and emergency response operations. The company has reportedly reached a valuation of $1.2 billion.
The venture was conceived by Palmer Luckey, founder of defence technology company Anduril Industries, and Ben Lamm, co-founder of biotechnology company Colossal Biosciences.
Improving Military Working Dogs
Warhound aims to develop healthier dogs with improved longevity, speed, agility and scent-detection capabilities. The company plans to use genetic research, cloning and gene editing to address inherited health conditions and improve the suitability of dogs for demanding operational environments.
The initiative will initially focus on breeds such as Belgian Malinois and German Shepherds, which are widely used in military and police operations.
Combining Biotechnology with Defence Technology
The startup plans to combine Colossal Biosciences' expertise in cloning and genetic engineering with technology from Anduril. This includes protective equipment and digital systems designed to improve communication, situational awareness and safety for dogs and their handlers.
Warhound also aims to reduce US dependence on European suppliers of military working dogs, many of which do not qualify for active service after extensive training.
What Happens Next?
The company expects its first litters to arrive in 2027, according to reports, although its technology and operational plans are still under development. It also says it will work with the American Humane Society on animal welfare and training standards.
The project highlights the growing intersection of biotechnology and defence technology, while raising questions about the ethical implications of genetically modifying animals for military purposes.
